BEAM Stock Price Today (September 2026) — Beam Therapeutics Inc. Analysis & Key Metrics 2026-09-03
Beam Therapeutics Inc. (BEAM) is trading at $29.46, up 0.58% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $52.31 (77.6% upside).
- Volatility remains elevated (56.83% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (-94.20% YoY) alongside significant competitive pressures.
BEAM Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Beam Therapeutics Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $2.02B
P/E Ratio
Forward P/E: -6.21
Revenue Growth
Year over Year
Analyst Target
+77.6% upside potential
Key Investor Questions About BEAM
What investors need to know before buying
Based on current market data, BEAM presents a neutral technical setup with challenging fundamentals.
- Technicals say: Neutral (RSI 54.61)
- Fundamentals say: Challenging (declining revenue trends)
BEAM's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for BEAM investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $247.36M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, BEAM stock traded between $16.02 and $38.26—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 56.83% annualized volatility and β=1.84, the stock exhibits high sensitivity to market moves—making BEAM suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Beam Therapeutics (BEAM) Stock May Look Stretched As Sales Expectations Climb
Beam Therapeutics has delivered a sharp 86.5% share price gain over the past year, yet the stock screens as expensive on broader valuation checks, which leaves recent buyers paying up for its gene editing potential without clear support from traditional metrics. The 86.5% 1 year return highlights how strongly sentiment has swung in favor of Beam Therapeutics, even though the business is still early in its commercial journey. Expectations that Beam Therapeutics can eventually turn its gene...
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.
BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus
Beam Therapeutics posts a wider-than-expected Q2 loss. Revenues also miss estimates as it advances multiple genome-editing programs with key clinical milestones ahead.
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates
Beam Therapeutics (BEAM) delivered earnings and revenue surprises of -18.00% and -98.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates
Myriad (MYGN) delivered earnings and revenue surprises of -733.33% and -7.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Scribe’s Genetic Editing Aims to Prevent Heart Attacks
Scribe Therapeutics shares are up 30% since it raised $125 million in its initial public offering Friday. The cash will fund three clinical trials testing whether Scribe’s one-time treatments can halve the risk of heart attacks and strokes. Scribe’s therapies turn off the genetic instructions leading to high levels of damaging lipids, without having to cut a gene’s DNA strands like other one-shot genetic treatments in the clinic.
Scribe’s Genetic Editing Aims to Prevent Heart Attacks
Scribe Therapeutics shares are up 30% since it raised $125 million in its initial public offering Friday. The cash will fund three clinical trials testing whether Scribe’s one-time treatments can halve the risk of heart attacks and strokes. Scribe’s therapies turn off the genetic instructions leading to high levels of damaging lipids, without having to cut a gene’s DNA strands like other one-shot genetic treatments in the clinic.
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?
Beam Therapeutics' growing pipeline could reward patient investors.
Bank of America Securities Maintains Buy Rating for Beam Therapeutics (BEAM)
Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 10 affordable biotech stocks to buy right now. On July 8, Alec Stranahan from Bank of America Securities reaffirmed his Buy rating for Beam Therapeutics Inc. (NASDAQ:BEAM), following a favorable resolution announced by Prime Medicine regarding its arbitration with Beam. Stranahan forecasted a target price of $47, […]
Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics
Prime Medicine, Inc. (NASDAQ:PRME) is one of the best strong buy penny stocks to invest in now. Prime Medicine, Inc. (NASDAQ:PRME) announced on July 8 a positive, binding resolution of its previously disclosed arbitration with Beam Therapeutics, Inc. relating to the parties’ 2019 Collaboration and License Agreement. The company reported that the Tribunal declared that PM647, […]
Explore More Analysis for BEAM
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Beam Therapeutics Inc.
Beam Therapeutics Inc. (BEAM) is currently trading at $29.46. The RSI (14-day) is at 54.6, indicating neutral territory. Wall Street analysts have a consensus "Hold" recommendation. The mean analyst price target of $52.31 implies 77.6% upside from current levels. Volatility is high at 56.8% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Beam Therapeutics Inc. (BEAM): The trailing P/E ratio is -42.70, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is -6.21. Price-to-Book is 2.76. Price-to-Sales is 19.50. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 13 analysts covering BEAM, the consensus price target is $52.31. This represents a 77.6% upside from the current price of $29.46. The range spans from a low target of $26.00 to a high target of $80.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "Hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Beam Therapeutics Inc. (BEAM) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Beam Therapeutics Inc. (BEAM) investors include: 1. High volatility (56.8% annualized)—the stock can experience significant daily price swings. 2. Declining revenue (-94.2% YoY), indicating potential business headwinds. 3. Elevated short interest (35.0% of float) suggests significant bearish sentiment. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Beam Therapeutics Inc.'s (BEAM) current debt and financial health profile: Total debt stands at $247.36M. The debt-to-equity ratio is 23.17, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 14.57, indicating strong short-term liquidity. The quick ratio is 14.25. The company holds $1.15B in cash and equivalents. Free cash flow is negative at $-241,844,000, which could limit the company's ability to manage debt obligations.